Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,356.00
Bid: 12,390.00
Ask: 12,394.00
Change: 28.00 (0.23%)
Spread: 4.00 (0.032%)
Open: 12,364.00
High: 12,454.00
Low: 12,322.00
Prev. Close: 12,328.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

In Senegal, lack of cold storage limits COVID vaccine options

Mon, 11th Jan 2021 17:09

By Christophe Van Der Perre

DAKAR, Jan 11 (Reuters) - Senegal does not have the capacity
to store COVID-19 vaccines at ultra-low temperatures and would
prefer to receive vials that can be kept for longer under
ordinary refrigeration, the head of the country's vaccination
programme said on Monday.

A lack of cold storage means Senegal would only be able to
keep vaccines developed by AstraZeneca and Oxford
University, by China or Russia in the long term, as they do not
require a deep freeze, Ousseynou Badiane told Reuters.

Those being distributed by Moderna, which require
storage at minus 20 degrees Celsius (-4 F), and Pfizer
and BioNTech, which need to be kept at -70 degrees
Celsius, are less desirable. Senegal could store the Moderna
vaccine for 30 days and the Pfizer one for seven days but after
that they would be spoiled, Badiane added.

The Moderna and Pfizer vaccines "are not our first choice.
Our first choice is the vaccine that fits easily into the system
that exists, that doesn't require major investment," Badiane
told Reuters.

"If the vaccines are not used (in the right time frame) that
would be an enormous waste."

The situation in Senegal highlights the problems that poorer
countries with hot climates face in storing and distributing
vaccines, often in rural areas with unreliable power supplies.

It also shows how far behind some African countries are in
preparing to receive vaccines even as COVID-19 cases surge to
record levels.

Millions have already received inoculations in Western
countries and China, while Senegal is awaiting vaccines through
the World Health Organization-backed global COVAX scheme. This
programme is helping to finance deliveries to 92 developing
nations with limited or no means to buy vaccines on their own.

Senegal is no stranger to vaccination campaigns.

In four walk-in cold rooms in the capital Dakar, authorities
keep thousands of vials of yellow fever and hepatitis B vaccines
at between 2 and 8 degrees Celsius. It has one room that keeps
oral polio vaccines up to minus 25 degrees Celsius.

At the Fann hospital in Dakar, technicians are installing
seven new such rooms. But for now the lack of deep refrigeration
limits the country's options.

"If the option now is to take the (Pfizer or Moderna)
vaccines we... would have to redo all our logistics," Badiane
said.
(Writing by Edward McAllister;
Editing by Hereward Holland and Gareth Jones)

More News
4 Jul 2023 16:49

LONDON MARKET CLOSE: Tepid close after quiet day with US market closed

(Alliance News) - Stocks in London were largely higher on Tuesday, though the FTSE 100 slipped into the red amid weakness, while US markets were shut for the independence day holiday.

Read more
4 Jul 2023 12:08

LONDON MARKET MIDDAY: Stocks higher amid US holiday-thinned trade

(Alliance News) - Stock prices in London were higher at midday on Tuesday, with the absence of US markets and any major economic releases keeping trade muted.

Read more
4 Jul 2023 09:27

LONDON BROKER RATINGS: Dunelm, AstraZeneca and Persimmon cut

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
3 Jul 2023 18:26

AstraZeneca shares fall as lung cancer results not as strong as hoped

(Alliance News) - AstraZeneca PLC on Monday saw shares fall, as test results suggested a new lung cancer drug may be less successful than hoped, despite being generally positive.

Read more
3 Jul 2023 17:24

FTSE 100 inches lower as healthcare drags; miners rise

AstraZeneca down as lung cancer drug trial lags expectations

*

Read more
3 Jul 2023 17:11

European shares end lower as healthcare declines outweigh miner gains

STOXX 600 snaps four-day winning streak

*

Read more
3 Jul 2023 17:05

LONDON MARKET CLOSE: Blue chips lose early shine as US treads water

(Alliance News) - London's FTSE 100 ran out of steam on Monday to close little changed, while New York markets made a muted start to an abbreviated session ahead of Independence Day.

Read more
3 Jul 2023 12:42

Will UK stocks fare better as tech rally fades?

STOXX 600 up 0.1%

*

Read more
3 Jul 2023 12:05

LONDON MARKET MIDDAY: Miners and oil majors lead FTSE 100 march

(Alliance News) - European equities went into Monday afternoon on the up, with the FTSE 100 outperforming as it was supported by its natural resources sector and oil majors.

Read more
3 Jul 2023 11:37

The most anticipated recession is also the most postponed

STOXX 600 up 0.2%

*

Read more
3 Jul 2023 11:23

AstraZeneca shares drop as lung cancer trial update lags expectations

July 3 (Reuters) - AstraZeneca said on Monday an experimental precision drug slowed progression of lung cancer in a late-stage trial, but the company's shares fell as much as 6% as analysts said the benefits may not be as pronounced as hoped.

Read more
3 Jul 2023 09:07

LONDON MARKET OPEN: Stocks start second half in green amid PMIs

(Alliance News) - European markets rose at Monday's open, kicking off the start of the second half on a positive note, boosted by strong trading in Asia and New York,

Read more
3 Jul 2023 08:42

TOP NEWS: AstraZeneca, Daiichi hail datopotamab lung cancer trial

(Alliance News) - AstraZeneca PLC and Tokyo-based partner Daiichi Sankyo Co Ltd on Monday announced that their investigational antibody drug conjugate Datopotamab deruxtecan showed positive results in an advanced non-small cell lung cancer trial.

Read more
3 Jul 2023 07:57

AstraZeneca reveals mixed interim findings in lung cancer trial

(Sharecast News) - AstraZeneca announced on Monday that datopotamab deruxtecan, or 'Dato-DXd', has shown promising results in a trial in patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) who had previously received at least one therapy.

Read more
28 Jun 2023 11:54

IN BRIEF: AstraZeneca invests USD400 million in reforestation

AstraZeneca PLC - Cambridge-based pharmaceutical company - Announces USD400 million investment in global AZ Forest programme, aiming to plant 50 million trees by the end of 2025 and 200 million trees by 2030. Projects are in Brazil, India, Vietnam, Ghana and Rwanda. The programme is focused on reforestation, biodiversity and community resilience and spans over 100,000 hectares worldwide.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.